CAMP4 THERAPEUTICS (CAMP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CAMP4 THERAPEUTICS

NasdaqGM•Healthcare•Biotechnology

$4.41-0.08(-0.02%)Market closed

Market Cap

$233.46M

P/S

55.4x

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 49/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (16/25); weakest: Cash & Earnings Quality (7/25).

Profitability11/25

Growth16/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality7/25

Strengths

Growing revenueLong cash runwayInterest easily coveredConsistent growth

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 55.4x5y range 9.7x – 58.9x

Currently near its 5-quarter median.

P/B · 7.5x5y range 0.4x – 7.5x

Currently above its 6-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $233.46M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.22M
Q. Revenue: $1.78M
TTM EBITDA: $-51.04M
TTM Op. Income: $-52.88M
Q. Op. Income: $-13.38M
TTM Net Income: $-107.24M
Q. Net Income: $-33.53M
EPS: $-0.58
Shares Out.: $57.93M

$4.22M in TTM revenue grew 40.2% YoY, reaching $1.78M last quarter. TTM EBITDA of $-51.04M and TTM operating income of $-52.88M show growth is flowing through to the bottom line. However, net income is negative at $107.24M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -724.0%
Op. Margin: -752.1%
Net Margin: -1884.8%

Op. margin of -752.1% is up 118.2% YoY — cost efficiency is improving. Net margin at -1884.8% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 55.4x
P/B Ratio: N/A

P/S of 55.4x and P/B of 0.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $93.43M
Cash: $86.40M
Long-Term Debt: N/A
Book Value: $-693,000
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-12.69M
TTM Free Cash Flow: $-28.72M
FCF Margin: -681.2%
FCF / Net Income: 0.3

TTM FCF of $-28.72M on $-12.69M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 59% — a weakening trend.